Manila Times Business
ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
CHICAGO, June 1, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-targeted CAR-T therapy, achieved a 66.7% objective response rate (ORR) in patients with Late-line refractory hepatocellular carcinoma (HCC). The data, selected for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlight a potential new benchmark for patients who have exha
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
NVIDIA Vera BlueField-4 STX Brings Agentic AI Storage Processing With In-Silicon Security
1h ago
NVIDIA Vera Rubin Ramps Into Full Production to Power Agentic AI Factories Worldwide
1h ago
NVIDIA DSX Gives Infrastructure Builders the Playbook for AI Factories
1h ago
Embracing a Zero-Carbon Future | The 6th LiuGong Global Customer Day Held in Liuzhou
1h ago